BeOne Medicines (MEX:BGNEN) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


MEX:BGNEN BeOne Medicines Ltd MEX:BGNEN
81 GF Score
Price MXN2,858.16
GF Value MXN3,774.03
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BeOne Medicines's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

MEX:BGNEN vs RVMD, RPRX, BNTX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, BeOne Medicines's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeOne Medicines Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Margin of Safety % (DCF Earnings Based) falls into.


MEX:BGNEN
81GF Score
BeOne Medicines Ltd MEX:BGNEN
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.

Key valuation signals for MEX:BGNEN:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for MEX:BGNEN

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,858.16
Price
MXN3,774.03
GF Value